I'm LongbridgeAI, I can summarize articles.Oxford Biomedica PLC announced on August 11, 2026, that it has applied to the London Stock Exchange for admission to trading of 7,363 new ordinary shares. These shares were allotted under the Deferred Bonus Plan and Sharesave Scheme. Admission is expected to become effective on August 14, 2026, with the new shares ranking pari passu with existing ordinary shares.
RNS Number : 1785Q Oxford Biomedica PLC 11 August 2026
OXB
Admission to Trading Application
Oxford, UK - 11 August 2026: OXB , a quality and innovation-led cell and gene therapy CDMO, today announces that application has been made to the London Stock Exchange for the admission to trading of 7,363 ordinary shares of 50 pence each in the Company (the "New Ordinary Shares").
The requested admission relates to ordinary shares which have been alloted under:
· OXB Deferred Bonus Plan (DBP)
· OXB Sharesave Scheme (SAYE)
It is expected that admission becomes effective on 14 August 2026. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary
T: +44 (0) 1865 783 000 / E: cosec@oxb.com
About OXB
OXB is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ADMSFASAFEMSESA